Cytopia zeroes in on brain
Monday, 17 November, 2008
Melbourne biotech Cytopia has commencing dosing patients in its Phase Ib/II trial of its vascular disrupting agent CYT997 in glioblastoma multiforme.
The trial will investigate the activity of CYT997 in combination with carboplatin and etoposide, common anti-cancer drugs.
CYT997 has been shown to ablate tumour blood vessels as well as inhibiting tubulin, thus affecting tumour cell replication. The compound is also being tested in multiple myeloma.
The trial will be held at Frankston Hospital in Victoria, with a second site in Sydney planned.
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
